New anemia drug candidate put to the test against market leader

NCT ID NCT06919861

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This trial compares a new erythropoietin drug called Nanokine to the approved drug Eprex in healthy male volunteers. The goal is to see if Nanokine is absorbed and processed by the body similarly to Eprex, and whether it has a comparable effect on red blood cell production. Each volunteer receives a single injection of both drugs, one after a 28-day break, and researchers measure drug levels and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Erythropoietin alfa (Nanokine and Eprex)
What this could lead to
If Nanokine proves similar to Eprex, it could become a more affordable alternative for treating anemia.
What could go wrong
This is an early-phase study in healthy volunteers, so results may not predict effects in patients with anemia. The drug may still fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 44 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male, aged 18 to 45 years. 2. Body weight 50 kg - 70 kg, BMI 18 - 28 kg/m², calculated per Metropolitan Index 1983 for adults. 3. At the time of screening, the subject is determined to be healthy by the investigator through a general clinical examination. 4. Laboratory test results for ECG, hematology and biochemistry (fasting glucose, urea, AST, ALT, creatinine) are within normal limits or assessed by the investigator as normal/eligible for study participation. 5. Screening test results: * Hemoglobin 125-175 g/L; * Vitamin B12 200-300 pg/mL; * Ferritin 22-400 ng/mL; * Transferrin 200-360 mg/dL; * Albumin 35-52 g/L; * Reticulocytes, red blood cells, and platelets within normal range; * Negative urine drug screen; * Negative HBsAg, anti-HCV and HIV. 6. Voluntarily participates in the study and has signed the informed consent form. Exclusion Criteria: 1. Lacks civil act capacity. 2. History of severe allergic reaction or anaphylaxis to biological products. 3. Use of Erythropoiesis Stimulating Agents (ESAs) or immunoglobulins within 3 months prior to screening. 4. History of seizures, epilepsy, or current disorders of the cardiovascular, respiratory, hepatic, renal, gastrointestinal, immune, hematologic, endocrine, nervous system, or psychiatric illness (as determined by the examining physician). 5. Recent illness within 2 weeks prior to screening (based on medical history and clinical examination). 6. History of blood loss \>450 mL or blood donation within 28 days prior to the first scheduled dose. 7. History of illicit drug use. 8. Recent history of alcohol abuse (defined as regular alcohol consumption within 6 months prior to screening, with average weekly intake \>21 units/week. One unit equals 8 g ethanol, equivalent to: 240 mL (half a glass) of beer, or 100 mL (1 glass) of wine, or 25 mL (1 shot) of spirits). 9. Recent history of tobacco abuse (defined as smoking on average \>10 cigarettes/day within 3 months prior to screening, or inability to abstain from smoking throughout the study period). 10. Excessive caffeine consumption (more than 5 cups of coffee per day). 11. Special dietary habits or inability to consume meals provided by the study site. 12. Currently participating in another clinical study, or has participated in a clinical study with another investigational product within the last 3 months. 13. Planning to conceive during the study period or unwilling to use contraception throughout the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pharmacokinetics and pharmacodynamics in healthy volunteers are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.